tbuckley/cabot-search huggingface dataset:
The Prevalence and Determinants of Cognitive Deficits and Traditional Diabetic Complications in the Severely Obese
Authors: Brian C. Callaghan, Evan L. Reynolds, Mousumi Banerjee, Ericka Chant, Emily Villegas-Umana, Thomas W. Gardner, Kristen Votruba, Bruno Giordani, Rodica Pop-Busui, Subramaniam Pennathur, Eva L. Feldman
Journal: Diabetes Care (2020)

OBJECTIVE To determine the prevalence of cognitive deficits and traditional diabetic complications and the association between metabolic factors and these outcomes. RESEARCH DESIGN AND METHODS We performed a cross-sectional study in severely obese individuals before bariatric surgery. Lean control subjects were recruited from a research website. Cognitive deficits were defined by the National Institutes of Health (NIH) Toolbox (&amp;lt;5th percentile for lean control subjects). Cardiovascular autonomic neuropathy (CAN) was defined by an expiration-to-inspiration (E-to-I) ratio of &amp;lt;5th percentile for lean control subjects. Retinopathy was based on retinal photographs and nephropathy on the estimated glomerular filtration rate (&amp;lt;60 mg/dL) and/or the albumin-to-creatinine ratio (ACR) (≥30 mg/g). NIH Toolbox, E-to-I ratio, mean deviation on frequency doubling technology testing, and ACR were used as sensitive measures of these outcomes. We used multivariable linear regression to explore associations between metabolic factors and these outcomes. RESULTS We recruited 138 severely obese individuals and 46 lean control subjects. The prevalence of cognitive deficits, CAN, retinopathy, and nephropathy were 6.5%, 4.4%, 0%, and 6.5% in lean control subjects; 22.2%, 18.2%, 0%, and 6.1% in obese participants with normoglycemia; 17.7%, 21.4%, 1.9%, and 17.9% in obese participants with prediabetes; and 25.6%, 31.9%, 6.1%, and 16.3% in obese participants with diabetes. Waist circumference was significantly associated with cognitive function (−1.48; 95% CI −2.38, −0.57) and E-to-I ratio (−0.007; 95% CI −0.012, −0.002). Prediabetes was significantly associated with retinal function (−1.78; 95% CI −3.56, −0.002). CONCLUSIONS Obesity alone is likely sufficient to cause cognitive deficits but not retinopathy or nephropathy. Central obesity is the key metabolic risk factor.
Abstract 12649: Remote, Integrated Algorithm-based CV Risk Management Program Improves Hypertension and LDL Control
Authors: Naomi D Fisher, Jorge Plutzky, Christopher P Cannon, David Zelle, Anton B Dodek, Calum A MacRae, Benjamin M Scirica, Thomas A Gaziano
Journal: Circulation (2019)

Hypertension (HTN) and hypercholesterolemia often coexist, and impart greater risk when they do. Given prior success with the remote management of HTN and LDL, we hypothesized that an integrated re...
Efficacy and Safety of Bevacizumab in Combination with Carboplatin and Paclitaxel for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer
Authors: K. Yoh, K. Goto, H. Ohmatsu, S. Niho, S. Umemura, Y. Ohe
Journal: Annals of Oncology (2012)
Calcitonin Receptor Neurons in the Mouse Nucleus Tractus Solitarius Control Energy Balance via the Non-aversive Suppression of Feeding
Authors: Wenwen Cheng, Ian Gonzalez, Warren Pan, Anthony H. Tsang, Jessica Adams, Ermelinda Ndoka, Desiree Gordian, Basma Khoury, Karen Roelofs, Simon S. Evers, Andrew MacKinnon, Shuangcheng Wu, Henriette Frikke-Schmidt, Jonathan N. Flak, James L. Trevaskis, Christopher J. Rhodes, So-ichiro Fukada, Randy J. Seeley, Darleen A. Sandoval, David P. Olson, Clemence Blouet, Martin G. Myers
Journal: Cell Metabolism (2020)

To understand hindbrain pathways involved in the control of food intake, we examined roles for calcitonin receptor (CALCR)-containing neurons in the NTS. Ablation of NTS Calcr abrogated the long-term suppression of food intake, but not aversive responses, by CALCR agonists. Similarly, activating CalcrNTS neurons decreased food intake and body weight but (unlike neighboring CckNTS cells) failed to promote aversion, revealing that CalcrNTS neurons mediate a non-aversive suppression of food intake. While both CalcrNTS and CckNTS neurons decreased feeding via projections to the PBN, CckNTS cells activated aversive CGRPPBN cells while CalcrNTS cells activated distinct non-CGRP PBN cells. Hence, CalcrNTS cells suppress feeding via non-aversive, non-CGRP PBN targets. Additionally, silencing CalcrNTS cells blunted food intake suppression by gut peptides and nutrients, increasing food intake and promoting obesity. Hence, CalcrNTS neurons define a hindbrain system that participates in physiological energy balance and suppresses food intake without activating aversive systems.
JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency
Authors: Fahad Alsohime, Marta Martin-Fernandez, Mohamad-Hani Temsah, Majed Alabdulhafid, Tom Le Voyer, Malak Alghamdi, Xueer Qiu, Najla Alotaibi, Areej Alkahtani, Sofija Buta, Emmanuelle Jouanguy, Ayman Al-Eyadhy, Conor Gruber, Gamal M. Hasan, Fahad A. Bashiri, Rabih Halwani, Hamdy H. Hassan, Saleh Al-Muhsen, Nouf Alkhamis, Zobaida Alsum, Jean-Laurent Casanova, Jacinta Bustamante, Dusan Bogunovic, Abdullah A. Alangari
Journal: New England Journal of Medicine (2020)

Deficiency of ubiquitin-specific peptidase 18 (USP18) is a severe type I interferonopathy. USP18 down-regulates type I interferon signaling by blocking the access of Janus-associated kinase 1 (JAK1) to the type I interferon receptor. The absence of USP18 results in unmitigated interferon-mediated inflammation and is lethal during the perinatal period. We describe a neonate who presented with hydrocephalus, necrotizing cellulitis, systemic inflammation, and respiratory failure. Exome sequencing identified a homozygous mutation at an essential splice site on USP18. The encoded protein was expressed but devoid of negative regulatory ability. Treatment with ruxolitinib was followed by a prompt and sustained recovery. (Funded by King Saud University and others.).
Cetuximab in Combination with Capecitabine and Cisplatin as First-Line Treatment in Advanced Gastric Cancer: Randomized Controlled Phase III Expand Study
Authors: F. Lordick, G. Bodoky, H. Chung, G. Kurteva, Y. Kang, S.C. Oh, P. Salman, H. Goette, H. Melezinkova, M. Moehler
Journal: Annals of Oncology (2012)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Authors: L.-T. Chen, E. Martinelli, A.-L. Cheng, G. Pentheroudakis, S. Qin, G.S. Bhattacharyya, M. Ikeda, H.-Y. Lim, G.F. Ho, S.P. Choo, Z. Ren, H. Malhotra, M. Ueno, B.-Y. Ryoo, T.C. Kiang, D. Tai, A. Vogel, A. Cervantes, S.-N. Lu, C.-J. Yen, Y.-H. Huang, S.-C. Chen, C. Hsu, Y.-C. Shen, J. Tabernero, Y. Yen, C.-H. Hsu, T. Yoshino, J.-Y. Douillard
Journal: Annals of Oncology (2020)
Efficacy and Safety of Dose-Dense Chemotherapy with Modified TCF Regimen (TCF-DD) in Elderly Patients with Metastatic Gastric Cancer (MGC)
Authors: G. Tomasello, W. Liguigli, S. Lazzarelli, R. Poli, F.M. Negri, L. Toppo, M. Ratti, M. Brighenti, F. Gerevini, R. Passalacqua
Journal: Annals of Oncology (2012)
Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma.
Authors: Ishwaria Mohan Subbiah, Apostolia Maria Tsimberidou, Aung Naing, Vivek Subbiah, Ahmed Omar Kaseb, Siqing Fu, David S. Hong, Sarina Anne Piha-Paul, Jennifer J. Wheler, Filip Janku, Kenneth R. Hess, Gerald Steven Falchook, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2012)

e13020 Background: Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few effective therapeutic options. We compared prognostic factors and clinical outcomes of CC/GC pts treated on phase I trials with that of their first-, second-line and last Food and Drug Administration (FDA)-approved therapy given in setting of metastatic disease. Methods: We retrospectively reviewed electronic medical records of patients with GC and CC evaluated in the phase I program clinic from November 2004 to March 2011. Results: Of the 72 patients with CC or GC, 32 (44%) were not enrolled on a trial mainly due to clinical deterioration (n=25). Of 40 treated patients (GC=6; CC=34; median age 60 years; median prior systemic therapies = 3), 8 (20%) had stable disease (SD) &gt; 6 months; 3 (8%) achieved a partial response (PR); SD &gt; 6 months/PR was observed mainly on protocols with hepatic arterial infusion drug administration and/or angiogenic inhibitors, anti-her2/neu agents or a novel MAPK/ERK kinase (MEK) inhibitor. Median progression-free survival (PFS) on phase I trials was 2.0 months (95% CI 1.7, 2.8) versus 3.0 months (95% CI 2.4, 5.0; p=0.95), 3.0 months (95% CI 2.3, 4.6; p=0.98), and 3.0 months (95% CI 2.4, 3.9; p=0.79) for their first-, second-, and last systemic therapy with FDA-approved agents given in the metastatic setting, respectively. In univariate analysis, factors associated with a shorter Phase I PFS were &gt; 3 metastatic sites, elevated ALT (&gt;56 IU/L), serum creatinine (&gt;1.6mg/dL), and CA19-9 (&gt;35U/mL). Conclusions: In heavily pretreated patients, PFS in the clinical trials setting remained poor but did not differ significantly from that of their first-line, second-line, and last prior therapy with FDA-approved agents. Response rate (SD &gt;6 months/PR) of 28% was seen in trials with locoregional treatment or inhibitors of angiogenesis, her2/neu or MEK.
Pathological Response of Synchronous Liver Metastases from Colorectal Cancer Treated with Bevacizumab Plus MFOLFOX6 in an Analysis of a Phase II Study of Neoadjuvant Chemotherapy
Authors: Y. Katayose, J. Yamauchi, M. Oikawa, N. Sakurai, H. Musya, H. Shimamura, K. Miura, K. Nakagawa, S. Egawa, M. Unno
Journal: Annals of Oncology (2012)
Final Results of a Randomized Phase II Study of TSU-68 after Transarterial Chemoembolisation in Japanese Patients with Unresectable Hepatocellular Carcinoma.Chemoembolization
Authors: S. Kaneko, Y. Inaba, F. Kanai, T. Aramaki, T. Yamamoto, T. Tanaka, K. Yamakado, M. Kudo, K. Imanaka, Y. Arai
Journal: Annals of Oncology (2012)
P-0199 Mechanisms Mediating The Negative Interaction Between Oxaliplatin and Epidermal Growth Factor Receptor Inhibitors in Patients With KRAS Mutant Colorectal Cancer
Authors: Daniel Freeman, Selam Ogbagabriel, Jiansong Xie, Juan Gloria, Nicholas Potter, Josh Dekeyser, Robert Radinsky
Journal: Annals of Oncology (2012)
Femtosecond laser-assisted versus phacoemulsification cataract surgery (FEMCAT): a multicentre participant-masked randomised superiority and cost-effectiveness trial
Authors: Cedric Schweitzer, Antoine Brezin, Beatrice Cochener, Dominique Monnet, Christine Germain, Stephanie Roseng, Remi Sitta, Aline Maillard, Nathalie Hayes, Philippe Denis, Pierre-Jean Pisella, Antoine Benard, Cati Albou-Ganem, Jean-Louis Arné, Emilie Bardet, Antoine Benard, Catherine Bourreau, Antoine Brezin, Olivier Chatoux, Catherine Cochard, Beatrice Cochener, Joseph Colin, Philippe Denis, Vincent Fortoul, Jerome Galet, Florence Galliot, Nicolas Georges, Christine Germain, Anne Gimbert, Margaux Guillard, Thomas Habay, Nathalie Hayes, Laurent Kodjikian, Aline Maillard, Emilie Merce, Dominique Monnet, Minh Nguyen, Romain Nicolau, Laurent Piazza, Pierre-Jean Pisella, Jean Rateau, Sophie Regueme, Stephanie Roseng, Jean-Jacques Sarragoussi, Cedric Schweitzer, Remi Sitta, David Touboul, Guillaume Vandenmeer
Journal: The Lancet (2020)
Abstract 483: Out of Hospital Cardiac Arrest Outcomes After Transitioning to Pit Crew Model
Authors: Mohinder Reddy Vindhyal, Paul M Ndunda, Shravani Vindhyal, Brent Duran
Journal: Circulation (2019)

Introduction: One of the leading causes of untimely death as per the Resuscitation Outcomes Consortium Epistry for cardiac arrest is out of hospital cardiac arrest (OHCA). Adoption of the choreographed approach of the pit crew model resuscitation improved outcomes after OHCA in some previous studies. Hypothesis: Compare outcomes post OHCA before and after adopting a pit crew model approach in one of the largest counties in Kansas. Methods: The data was collected before (2010 – 2012) and after the pit crew (2013-2016) approach from 2010 to 2016. The patient demographics and resuscitation variables were similar and comparable including the emergency and fire department personnel. The primary outcome was the proportion of patients having sustained return of spontaneous circulation (ROSC). Secondary outcomes were average number of pauses &gt;10 seconds, cerebral performance post return of spontaneous circulation, and average cardio-pulmonary resuscitation (CPR) cycles to ROSC. Results: The patients who had sustained ROSC post pit crew approach was 67.9% vs 32.1% (p=&lt; 0.001). Average number of CPR pause time &gt; 10 seconds post pit crew model was 1 vs 5 (p=0.01). Cerebral performance post return of spontaneous circulation using pit crew approach with good cerebral performance was 47% vs 56% (p=0.2), moderate cerebral disability was 17% vs 23% (p=0.19), severe cerebral disability was 8% vs 11% (p=0.44) and in coma/vegetative state was 8% vs 16% (p=0.001). Average CPR cycles to ROSC was 6.63. Conclusion: This focused model of high-quality CPR performance with individualized assigned tasks with minimal interruptions has shown increased numbers of sustained ROSC. The pit crew model approach also has showed decline in the rates of cerebral performance especially with moderate and severe cerebral performance including the patients in coma or vegetative state which is mainly through continuous cerebral perfusion pressures. More studies with better follow-up care in coordination with hospital outcomes will be key for the pit crew approach to be adopted.
Use of Powder in the Genital Area and Ovarian Cancer Risk
Authors: Dana R. Gossett, Marcela G. del Carmen
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of Bone Mineral Density (BMD) in Early Breast Cancer (EBC) Patients Treated With Up-Front or Switch Schedules of Aromatase Inhibitors (AIS): Results of a Single Centre Retrospective Study
Authors: P. Seminara, A. Iannace, G. Manna, T. Losanno, A. Emiliani, E. Franzese, L. Frati
Journal: Annals of Oncology (2012)
A common signaling pathway leading to degranulation in mast cells and its regulation by CCR1‐ligand
Authors: Hyeun Wook Chang, Shiro Kanegasaki, Fansi Jin, Yifeng Deng, Zhiwei You, Jae‐Hoon Chang, Dong Young Kim, Maheshwor Timilshina, Jae‐Ryong Kim, Youn Ju Lee, Noriko Toyama‐Sorimachi, Tomoko Tsuchiya
Journal: Allergy (2020)

Signal transduction pathways mediated by various receptors expressed on mast cells are thought to be complex, and inhibitory signals that turn off activating signals are not known.Upstream signaling cascades mediated by several known receptors in bone marrow-derived mast cells that lead to degranulation and mediator release were studied by immunoblotting and immunoprecipitation. Small interfering RNAs and knockout mice were used to confirm findings.All ligands tested including IgE/Ag, SCF, HSP70, CCL3, and its valiant eMIP induced phosphorylation of linker for activation of T cells (LAT), which triggered their receptor-mediated downstream signaling cascades that controlled degranulation and mediator release. Phosphorylation of lymphocyte-specific protein kinase (Lck) was induced by each ligand, which commonly played an indispensable role in LAT phosphorylation. In contrast, phosphorylation of spleen tyrosine kinase was additionally induced in cells stimulated only with IgE/Ag and SCF, which is also associated with LAT phosphorylation in part. Degranulation and mediator release induced by IgE/Ag, SCF, or HSP70 were enhanced by nanomolar doses of CCR1 ligands CCL3 and eMIP via enhanced LAT phosphorylation. On the other hand, micromolar doses of CCR1 ligand inhibited degranulation and mediator release from mast cells stimulated with IgE/Ag, SCF, or HSP70 by de-phosphorylation of phosphorylated Lck with Src homology region 2 domain-containing phosphatase-1.Linker for activation of T cells plays a central role in signal transduction pathways in mast cells stimulated with any ligand tested. Dose-dependent alternate costimulation and inhibition of CCR1 ligands in IgE/Ag-, SCF-, or HSP70-stimulated mast cells occur at the level of Lck-LAT phosphorylation.
The impact of repeated vaccination using 10-year vaccination history on protection against influenza in older adults: a test-negative design study across the 2010/11 to 2015/16 influenza seasons in Ontario, Canada
Authors: Jeffrey C Kwong, Hannah Chung, James KH Jung, Sarah A Buchan, Aaron Campigotto, Michael A Campitelli, Natasha S Crowcroft, Jonathan B Gubbay, Timothy Karnauchow, Kevin Katz, Allison J McGeer, J Dayre McNally, David C Richardson, Susan E Richardson, Laura C Rosella, Kevin L Schwartz, Andrew Simor, Marek Smieja, George Zahariadis
Journal: Eurosurveillance (2020)

IntroductionAnnual influenza vaccination is recommended for older adults, but evidence regarding the impact of repeated vaccination has been inconclusive.AimWe investigated vaccine effectiveness (VE) against laboratory-confirmed influenza and the impact of repeated vaccination over 10 previous seasons on current season VE among older adults.MethodsWe conducted an observational test-negative study in community-dwelling adults aged > 65 years in Ontario, Canada for the 2010/11 to 2015/16 seasons by linking laboratory and health administrative data. We estimated VE using multivariable logistic regression. We assessed the impact of repeated vaccination by stratifying by previous vaccination history.ResultsWe included 58,304 testing episodes for respiratory viruses, with 11,496 (20%) testing positive for influenza and 31,004 (53%) vaccinated. Adjusted VE against laboratory-confirmed influenza for the six seasons combined was 21% (95% confidence interval (CI): 18 to 24%). Patients who were vaccinated in the current season, but had received no vaccinations in the previous 10 seasons, had higher current season VE (34%; 95%CI: 9 to 52%) than patients who had received 1-3 (26%; 95%CI: 13 to 37%), 4-6 (24%; 95%CI: 15 to 33%), 7-8 (13%; 95%CI: 2 to 22%), or 9-10 (7%; 95%CI: -4 to 16%) vaccinations (trend test p = 0.001). All estimates were higher after correcting for misclassification of current season vaccination status. For patients who were not vaccinated in the current season, residual protection rose significantly with increasing numbers of vaccinations received previously.ConclusionsAlthough VE appeared to decrease with increasing numbers of previous vaccinations, current season vaccination likely provides some protection against influenza regardless of the number of vaccinations received over the previous 10 influenza seasons.
Profile of Doses to Organs at Risk Using 3-D Conformal Radiotherapy (3-DCRT) Versus Intensity Modulated Radiotherapy (IMRT) in Postoperative Radiotherapy of Periampullary Cancers: Implications for Radiation Dose Escalation
Authors: A. Bahl, R. Kapoor, P. Tomar, A.O. Singh, R. Gupta, S.C. Sharma
Journal: Annals of Oncology (2012)
A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903
Authors: A. Nishiyama, H. Yoshioka, K. Kunimasa, K. Hotta, N. Nogami, T. Kozuki, S. Harita, N. Takigawa, M. Tanimoto, K. Kiura
Journal: Annals of Oncology (2012)
Denosumab Compared with Zoledronic Acid for Preventing Skeletal Complications in Patients with Multiple Myeloma: A Randomized, Phase 3, Double-Blind, Double-Dummy Trial
Authors: A. Palumbo, B.G. Durie, N. Raje, R. García Sanz, O. Sezer, K. Shimizu, E. Terpos, W. Willenbacher, Y. Qian, A. Balakumaran
Journal: Annals of Oncology (2012)
Safety and Efficacy of Cisplatin Plus 5-Fu and Cetuximab in HPV-Positive and HPV-Negative Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Analysis of the Phase III Extreme Trial
Authors: A. Psyrri, L. Licitra, B. De Blas, I. Celik, J.B. Vermorken
Journal: Annals of Oncology (2012)
Activity of Afatinib in Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations in Lux-Lung 3, A Phase III Trial of Afatinib or Cisplatin/Pemetrexed in EGFR Mutation-Positive Lung Cancer
Authors: J.C. Yang, M. Schuler, N. Yamamoto, K.J. O'Byrne, V. Hirsh, T.S.K. Mok, D. Massey, V. Zazulina, M. Shahidi, L.V. Sequist
Journal: Annals of Oncology (2012)
Atrial Failure as a Clinical Entity
Authors: Felipe Bisbal, Adrian Baranchuk, Eugene Braunwald, Antoni Bayés de Luna, Antoni Bayés-Genís
Journal: Journal of the American College of Cardiology (2020)

Atrial dysfunction has been widely considered a marker or consequence of other cardiac conditions rather than the cause itself. Here, we propose the term atrial failure as a clinically relevant entity, defined as any atrial dysfunction causing impaired heart performance, symptoms, and worsening quality of life or life expectancy. Aspects of the etiology, mechanisms, and consequences of atrial failure are discussed. Recent advances in cardiac electrophysiology and imaging have improved our understanding of the highly complex atrial anatomy and function, underlying the paramount importance of the atria in optimal heart performance. It is time to reappraise the concept of the failing atrium as a primary cause or aggravating factor of the symptoms in many of our patients. The concept of atrial failure may foster basic and translational research to gain a better understanding of how to identify and manage atrial dysfunction.
Visualization of AMPA receptors in living human brain with positron emission tomography
Authors: Tomoyuki Miyazaki, Waki Nakajima, Mai Hatano, Yusuke Shibata, Yoko Kuroki, Tetsu Arisawa, Asami Serizawa, Akane Sano, Sayaka Kogami, Tomomi Yamanoue, Kimito Kimura, Yushi Hirata, Yuuki Takada, Yoshinobu Ishiwata, Masaki Sonoda, Masaki Tokunaga, Chie Seki, Yuji Nagai, Takafumi Minamimoto, Kazunori Kawamura, Ming-Rong Zhang, Naoki Ikegaya, Masaki Iwasaki, Naoto Kunii, Yuichi Kimura, Fumio Yamashita, Masataka Taguri, Hideaki Tani, Nobuhiro Nagai, Teruki Koizumi, Shinichiro Nakajima, Masaru Mimura, Michisuke Yuzaki, Hiroki Kato, Makoto Higuchi, Hiroyuki Uchida, Takuya Takahashi
Journal: Nature Medicine (2020)
Mycafungin Prophylaxis for Adult Acute Leukemia Patients Undergoing Induction Chemotherapy
Authors: Hyunkyung Park, Youk Jeonghwan, Wan Beom Park, Dong-Yeop Shin, Junshik Hong, Inho Kim, Kim Nam Joong, Hyun Jung Lee, Hyo Jung Kim, Sung-Soo Yoon, Youngil Koh
Journal: Blood (2017)